Selective Serotonin Reuptake Inhibitors Reduce Longitudinal Growth in Risperidone-Treated Boys - 21/09/18
, James A. Mills, MS 3, Lefkothea Karaviti, MD, PhD 2, Antonio L. Teixeira, MD, PhD, MSc 4, Babette S. Zemel, PhD 5, Jose M. Garcia, MD, PhD 6Abstract |
Objectives |
To examine whether selective serotonin reuptake inhibitors (SSRIs) inhibit longitudinal growth in children and adolescents, particularly in the early stages of puberty, using a sample of convenience comprising risperidone-treated boys.
Study design |
Data from four clinic-based studies in risperidone-treated 5- to 17-year-old boys with no general medical conditions were combined for this analysis. Anthropometric measurements and psychotropic treatment history were extracted from the medical and pharmacy records. Linear mixed effects regression analyses examined the association between SSRI use and change in age-sex-specific height and body mass index z scores, after adjusting for relevant confounders.
Results |
Risperidone-treated boys (n = 267; age: 12.7 ± 2.7 years), 71% of whom had ever taken an SSRI, contributed to the analysis. After adjusting for age, psychostimulant and antipsychotic use, and time in the study, both the duration of SSRI use as well as the cumulative dose were inversely associated with height z score after age 11 years (P < .0001). After adjusting for baseline height, duration of SSRI use was most strongly inversely associated with height z score in Tanner stages 3 and 4 boys who took SSRIs continuously (r = −0.69, P < .009). No association was observed with body mass index z score.
Conclusions |
In risperidone-treated boys, SSRI use is associated with reduced longitudinal growth, particularly in those undergoing puberty. Whether adult height or other metabolic or psychological outcomes are affected remains to be determined.
Le texte complet de cet article est disponible en PDF.Keywords : children, adolescents, height, growth, major depressive disorder, selective serotonin reuptake inhibitors
Abbreviations : BMI, GH, IGF, SSRI, TORDIA
Plan
| Funded by a 2005 and a 2007 Young Investigator Award, a Fraternal Order of Eagle Diabetes Research Center pilot grant, and by the National Institutes of Health (RR024979, R21MH080968, and K23MH085005). The content is solely the responsibility of the authors and does not necessarily represent the official views of the funding agency. J.G. receives funding support from Pfizer Inc and Aeterna Zentaris Inc. The other authors declare no conflicts of interest. |
|
| Portions of this study were presented as a poster at the annual meeting of the American Academy of Child and Adolescent Psychiatry, Washington, DC, October 25, 2017. |
Vol 201
P. 245-251 - octobre 2018 Retour au numéro
Article précédent
- 50 Years Ago in The Journal of Pediatrics : Phenylketonuria and Scleroderma
- Philip J. Hashkes
- Subsyndromal Manifestations of Depression in Children Predict the Development of Major Depression
- Mai Uchida, Maura Fitzgerald, Hilary Woodworth, Nicholas Carrellas, Caroline Kelberman, Joseph Biederman
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?